A venture capital firm founded in 2002 invests solely in life sciences companies and is currently investing from a US$35M private fund and a $50M government matching fund. Equity allocation size varies and can reach up to US$3M per deal. The firm is open to leading or co-investing. The firm focuses 70% on Asia and 30% on global deals and is currently seeking new opportunities.

Within life sciences, the firm is most interested in biotech therapeutics including biologics, small molecules, and drug formation. The firm considers all indications with a focus on neurodegeneration and psychology. The firm prefers assets ranging from preclinical to phase II. Historically the firm has invested in medical technology, agricultural biotech, and biotech R&D services, but will consider these sectors with less interest.

The firm is looking for experienced management teams with strong sector expertise. For domestic deals, the firm seeks an active role in its portfolio companies and would require a board seat on a case-by-case basis. For foreign deals, the firm prefers to syndicate with a strong lead that can work with investee companies closely.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A boutique venture capital firm founded in 2015 in Hong Kong is currently investing from its $100M fund in early stage cross-border technology companies in TMT and MedTech. The firm generally participates in Series A rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing, and is actively seeking new opportunities from across the world with a focus on companies in China, U.S. and Europe. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand aboard. The firm expects to make 8 new investments in the next 6 months.

The firm is most interested in medical devices such as minimally invasive surgical instruments, artificial intelligence and robots, diagnostic tools; and mobile health innovations. The firm is seeking innovations that have completed prototype. The firm would also consider therapeutics for large disease markets with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams. The firm can work with incomplete teams and contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request right of priority distribution rights or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity and advisory firm, based in Zürich, Switzerland, which has been founded in 1999. Along with providing private equity, the firm serves also as a corporate development and financial advisor to life science and technology companies through the firm’s VC and PE network. The firm has a primary focus on the Life Science sector and actively supports early stage companies in development. The firm has managed a €40M fund and is fundraising to close a larger fund in 2016. The firm focuses on companies based in Europe, though it would be open to US-based companies that have interest in establishing themselves in the European market and may have strong ties to Europe (i.e. representatives or office in Europe, European vendors, etc.).

The firm has a general interest in Life Sciences, especially concentrating on biotech therapeutics, diagnostics and medical devices of all subsectors as well as digital healthcare opportunities. With regard to indications the firm is agnostic and has worked in the past in oncology, cardiovascular, anti-infective, autoimmune, CNS and in the field of vaccine technology. When investing, the firm prefers preclinical to early clinical stage companies that have a first proof-of-concept in-vitro or/and in-vivo. The company is focusing on seed round opportunities and spin-offs in which the firm could actively engage. It would be advantageous if the product and service offering is based on a proprietary platform technology. The firm will look at commercialized/late stage products or technology far down the development timeline especially with respect to its business development activities offering.

The firm prefers a management team with experience in the industry, though understands that at the seed stage, there will be gaps in the management team that the firm will help to fill with own resources or drawing on its extensive network in the industry. The firm will also look at assets spun out of institutions including universities and research institutions or the pharmaceutical industry, and will support the scientist entrepreneurs in business development by integrating with the company and delivering managerial support where necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate VC firm based in Asia is focused on aggregating technologies in women’s health. The firm invests from an evergreen fund and is a multi-stage investor. Typical investments range from USD 1-5 million, but the fund may make larger tranched investments in the case of therapeutic opportunities. The firm invests in companies worldwide and can act as either a lead investor or co-investor.

The firm is currently focused on building a cluster of technologies in women’s health, across the therapeutic, medical device, diagnostic and healthcare IT sectors. The firm is particularly interested in reproductive health, triple-negative breast cancer, and ovarian cancer, but will consider any opportunity in women’s health. The firm will invest in technologies at any stage of development, including very early-stage technologies. In the medtech space, the firm has a preference for 510k pathways but will look at PMA opportunities if the technology is sufficiently interesting.

The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with global distribution and scale up.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early-stage seed fund based in Palo Alto, CA focuses on seed stage and sometimes Series A investments. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments. The firm is seeking opportunities from across the US with a focus on the Bay Area.

The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.

The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com